Patent directory · USPTO A61K / A61P
Patents matching “REGENERON PHARMACEUTICALS, INC.”
837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 9790273
Anti-HLA-B*27 antibodies and uses thereof
granted -
US 9771414
Human antibodies to ebola virus glycoprotein
granted -
US 9751921
Apelin fusion proteins and uses thereof
granted -
US 9751932
Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof
granted -
US 9724411
Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9
granted -
US 9718872
Human antibodies to middle east respiratory syndrome—coronavirus spike protein
granted -
US 9718881
Anti-Activin A antibodies and uses thereof
granted -
US 9708386
Modified chimeric polypeptides with improved pharmacokinetic properties
granted -
US 9700025
Genetically modified major histocompatibility complex animals
granted -
US 9700027
Non-human animals having a humanized signal-regulatory protein gene
granted -
US 9688764
Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies
granted -
US 9687566
Low affinity FCGR deficient mice
granted -
US 9675692
Stabilized formulations containing anti-DLL4 antibodies
granted -
US 9669069
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 9657099
Anti-glucagon antibodies
granted -
US 9655352
Humanized M-CSF mice
granted -
US 9657102
Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof
granted -
US 9650444
Anti-PDGFR-beta antibodies and uses thereof
granted -
US 9644018
Antibody modulators of APLNR
granted -
US 9637535
IL-33 antagonists and uses thereof
granted -
US 9636400
VEGF specific fusion protein antagonist formulations
granted -
US 9592271
Angiopoietin-based interventions for treating cerebral malaria
granted -
US 9587029
Human antibodies to the glucagon receptor and methods of use thereof
granted -
US 9580489
VEGF antagonist formulations suitable for intravitreal administration
granted